◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 2509

Qyuns Therapeutics Co., Ltd. (2509) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-10

Qyuns Therapeutics Co., Ltd. (2509) operates in the Biotechnology industry and is headquartered in Taizhou, China with about 337 employees. Its market capitalization is roughly CNY 4 billion. In the fiscal year ended 2025-12-31, 2509 reported CNY 807M in revenue and CNY 314M in net income.

Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, engages in the research and development of biologic therapies for autoimmune and allergic diseases in China.

Interactive charts & full statements →

2509 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total RevenueCNY 807MCNY 159MCNY 0MCNY 0M
Gross ProfitCNY 714MCNY 92MCNY 0M
Operating Income (EBIT)CNY 333M(CNY 342M)(CNY 515M)(CNY 325M)
Net IncomeCNY 314M(CNY 336M)(CNY 508M)(CNY 298M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2509 Free Cash Flow History

2509 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsCNY 1.6BCNY 984MCNY 796MCNY 1.0B
Total LiabilitiesCNY 921MCNY 763MCNY 495MCNY 374M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2509 viewer.

Other Companies in Biotechnology

← 2508All “0-9” companies2510 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.